Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins…
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Attention-deficit / hyperactivity disorder (ADHD) is one of the most common childhood mental health disorders that can continue into adulthood. This condition entails several recurring problems,…
Renal inflammation associated with SLE, also known as LN, is among the most serious manifestations of the disease. Until recently, no therapy was specifically approved for LN. Most treatments are…
Psychiatric disorders such as anxiety, posttraumatic stress disorder (PTSD), and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists…
Clarivate Epidemiology’s coverage of mild cognitive impairment (MCI) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in Europe. Treatment of glaucoma aims to lower and…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key mild cognitive impairment disease patient populations, covering 171…